IDEXX Laboratories Inc. (IDXX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
IDEXX Laboratories’s revenue went from $1.8B in fiscal 2016 to $4.3B in fiscal 2025, growth of about 10.3% a year.
Net income in fiscal 2025 was $1.1B, a net margin of 24.6%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $4.7B and net income $1.2B.
Free cash flow was $1.1B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 11% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7B | $4.3B | $3.9B | $3.7B | $3.4B | $3.2B | $2.7B | $2.4B | $2.2B | $2.0B | $1.8B |
| Gross profit | $2.9B | $2.7B | $2.4B | $2.2B | $2.0B | $1.9B | $1.6B | $1.4B | $1.2B | $1.1B | $975M |
| Operating income | $1.5B | $1.4B | $1.1B | $1.1B | $899M | $932M | $695M | $553M | $491M | $413M | $350M |
| Net income | $1.2B | $1.1B | $888M | $845M | $679M | $745M | $582M | $428M | $377M | $263M | $222M |
| EPS (diluted) | $14.84 | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 |
| R&D | $267M | $251M | $220M | $191M | $255M | $161M | $141M | $133M | $118M | $109M | $101M |
| Revenue growth | — | +10.4% | +6.5% | +8.7% | +4.7% | +18.8% | +12.4% | +8.8% | +12.4% | +10.9% | +10.8% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.4B | $1.2B | $929M | $907M | $543M | $756M | $648M | $459M | $400M | $373M | $339M |
| Capital spending | -$115M | -$125M | -$121M | -$134M | -$149M | -$120M | -$107M | -$155M | -$116M | -$74M | -$65M |
| Free cash flow | $1.3B | $1.1B | $808M | $773M | $394M | $636M | $541M | $304M | $284M | $299M | $274M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $1.0B | $1.2B | $837M | $72M | $820M | $747M | $183M | $302M | $369M | $283M | $304M |
| Stock-based pay | $65M | $60M | $60M | $60M | $50M | $38M | $31M | $39M | $25M | $24M | $20M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $180M | $288M | $454M | $113M | $144M | $384M | $90M | $124M | $472M | $392M |
| Debt | — | $578M | $737M | $818M | $891M | $958M | $1.0B | $782M | $1.0B | $1.3B | $1.2B |
| Equity | — | $1.6B | $1.6B | $1.5B | $609M | $690M | $632M | $177M | -$10M | -$54M | -$108M |
| Total assets | — | $3.4B | $3.3B | $3.3B | $2.7B | $2.4B | $2.3B | $1.8B | $1.5B | $1.7B | $1.5B |
| Shares (diluted) | 79M | 81M | 83M | 84M | 85M | 87M | 87M | 88M | 88M | 90M | 91M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 62.7% | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% | 56.7% | 56.1% | 55.7% | 54.9% |
| Operating margin | 32.3% | 31.6% | 28.9% | 30.0% | 26.7% | 29.0% | 25.7% | 23.0% | 22.2% | 21.0% | 19.7% |
| Net margin | 25.4% | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% |
| FCF margin | 28.0% | 24.6% | 20.7% | 21.1% | 11.7% | 19.8% | 20.0% | 12.6% | 12.8% | 15.2% | 15.4% |
| ROIC | — | 49.8% | 38.7% | 38.0% | 47.3% | 46.7% | 37.3% | 47.2% | 40.8% | 23.6% | 22.1% |
| ROE | — | 66.0% | 55.6% | 56.9% | 111.6% | 107.9% | 92.0% | 241.0% | -3963.3% | -486.4% | -204.9% |
Frequently asked questions
What is IDEXX Laboratories’s annual revenue?
$4.3B in fiscal 2025 and $4.7B over the twelve months to September 30, 2026.
How much profit does IDEXX Laboratories make?
Net income was $1.1B in fiscal 2025 (net margin 24.6%).
Is IDEXX Laboratories’s revenue growing?
Yes: revenue rose 10.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.